Moreover, feelings of aggression are frequently described in PD patients, and anger attacks have been proposed as a specific variant of panic attacks (8, 9) . Therefore, it would be interesting to assess whether the supposedly panic-specific challenge test with 35% CO 2 might induce other affective symptoms, such as aggression and depression.
In this pilot study, we compared PD patients without a history of depression and PD patients with comorbid (concurrent or lifetime) depressive disorder. Previously, PD plus major depressive disorder (MDD) patients were shown to react to the CO 2 provocation with increased anxiety symptoms, when compared with PD patients with no MDD (10) . We hypothesize that the CO 2 challenge will induce aggressive and depressive symptoms in only those PD patients with current or lifetime MDD.
Methods
Subjects were recruited at the Academic Anxiety Center, Maastricht, the Netherlands, an outpatient clinic specialized in anxiety disorders. All patients were evaluated by means of a clinical psychiatric interview, with an emphasis on anxiety and affective spectrum symptoms, and the structured Mini International Neuropsychiatric Interview (MINI, 11). Two experienced psychiatrists confirmed the diagnoses. Additionally, patients underwent a physical examination and routine blood tests. Patients who met DSM-IV (12) criteria for panic disorder (with or without agoraphobia) were informed about the experimental intervention and were invited to participate in the study. All participating patients gave written informed consent. The study was approved by the Investigation Review Board of the University of Maastricht and was conducted according to the Declaration of Helsinki. We excluded patients with other Axis 1 diagnoses, current or lifetime, except for those with comorbid MDD. We also excluded patients who were currently using benzodiazepines or antidepressant medication (washout period of 2 weeks, except for fluoxetine, with a washout period of 6 weeks) and patients with physical conditions that could be compromised by the challenge (for example, cardiovascular or pulmonary disease, epilepsy, pregnancy, or a known cerebral aneurysm).
Intervention
The experimental intervention was the CO 2 inhalation method, which is described in detail elsewhere (1, 13) . This procedure requires the inhalation of a single breath of a CO 2 (35%) and O 2 (65%) gas mixture.
Assessments
At baseline, just before the CO 2 inhalation, patients were asked to complete the Panic Symptom List (PSL), comprised of 13 items reflecting panic symptoms that are scored from 0 to 4. This scale has previously been used to assess experimental panic anxiety (14, 15) . Patients were also requested to complete the adapted short Profile of Mood States on Aggression (POMS-Ag) and on Depression (POMS-D) (16) , which comprises 7 mood states relating to depression (unhappy, miserable, depressed, downhearted, sad, gloomy, and lonely) and 7 relating to aggression (angry, bitter, annoyed, bad-tempered, furious, spiteful, and ready to fight), respectively, each scored from 0 to 4.
The other scales to be scored were a visual analogue scale (0 to 100) on anxiety (VAS-A), aggression (VAS-Ag), and depression (VAS-D). All these assessments were repeated immediately after the CO 2 challenge. The occurrence of a panic attack was defined as an increase of at least 25% on the VAS-A (that is, an increase of 25 points) and any increase on at least 4 PSL symptoms (17) .
Statistical Analysis
We analyzed the data with SPSS for Windows, version 11.0 (18) . We used Student's t test to test mean age differences and the chi-square test to test sex distribution. We tested between-group differences, using the nonparametric MannWhitney U test for unrelated samples, owing to nonnormal data distribution. Significance levels were set at P < 0.05.
Results
Patient characteristics are summarized in Table 1 . We included 25 PD patients in this study. Nine of these 25 patients (36%) had a comorbid lifetime depressive disorder (that is, PD plus MDD). Five of these 9 subjects met the criteria for a current depression. Baseline ratings did not differ between the 2 subgroups, and postchallenge ratings were significantly higher for the PD plus MDD group on all affective ratings, except for specific panic symptoms (Table 1) .
Discussion
This study demonstrates that a panic challenge may give rise to depressive and aggressive symptoms as well. This effect was most pronounced in the PD plus MDD group. Some studies previously used the challenge paradigm to assess PD patients with and without comorbid MDD. However, they were all restricted to anxiety symptoms for outcome measures.
The present study confirmed the higher increase in anxiety measures for the PD plus MDD group, as reported earlier by Verburg and colleagues (10) . In addition, we found a difference in the other affective dimensions of depression and aggression.
The role of MDD in this respect is not clear. It has been reported that ventilation of MDD patients decreases after a CO 2 challenge (19, 20) , whereas in PD patients, there is an increased ventilatory response (21) . This physiological reaction is paralleled by a lower increase in heart rate following a hyperventilation challenge in MDD patients, compared with PD and compared with MDD with sporadic panic attacks (22) . This mild physiological reaction is also reflected in the lack of psychological distress to this hyperventilation challenge, since it did not result in an increase in subjective units of discomfort sensations, which is comparable to our VAS assessment in MDD patients. Perna and others have shown that, when their panic and anxiety symptoms are measured, patients with an MDD (without panic attacks or PD) do not respond to this provocation method; rather, they react in the same way as healthy control subjects do (23) . Unfortunately, we have no data on other affective dimensions of aggression and depression in MDD patients. Neither Perna and colleagues (23) nor Verburg and colleagues (10) assessed these affects.
From these data, we infer that MDD and PD patients react to a panicogenic challenge in different ways. However, when both disorders are present, MDD is no longer protective against the challenge, and PD seems to determine the response.
Some limitations of the present study must be mentioned. Because we did not include a control group of depression patients without PD, we cannot say with any certainty whether the CO 2 challenge can increase aggressive or depressive feelings, even though this seems unlikely. Also, a control group of healthy subjects could have been included to control for the broader affective symptoms that might be raised by a CO 2 challenge. Another limitation of this study is the small sample of comorbid patients with depression and PD. A larger group would have made it possible to analyze possible differential effects of the CO 2 challenge in the subgroups. It would have been interesting to look at the effect of a lifetime depressive episode (in PD patients) as a trait marker that gives rise to a vulnerability to the experimental provocation of depressive and aggressive symptoms.
Future studies using the CO 2 challenge paradigm should take into account the assessment of affective spectrum symptoms for outcome measures. They should be targeted at assessing the effect of a CO 2 challenge on pure MDD patients (with present and lifetime MDD patients in separate groups) on the dimensions of aggression and depression. Also, future research needs to focus on assessing affective symptoms after a panic challenge in pure PD patients, compared with comorbid PD patients. 
